- Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
- Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
- Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
- Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
- Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
- Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
More ▼
Key statistics
On Thursday, Alpha Tau Medical Ltd (DRTS:NAQ) closed at 2.95, 9.26% above its 52-week low of 2.70, set on Dec 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.93 |
---|---|
High | 2.96 |
Low | 2.87 |
Bid | 2.88 |
Offer | 3.26 |
Previous close | 2.95 |
Average volume | 30.90k |
---|---|
Shares outstanding | 69.67m |
Free float | 38.00m |
P/E (TTM) | -- |
Market cap | 205.53m USD |
EPS (TTM) | -0.4203 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼